Colleen Silk on Novo Nordisk Performance at ASH25
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”I’m so proud to have attended the 2025 ASH Annual Meeting in Orlando over the weekend alongside so many talented colleagues from our Hemoglobinopathies and Rare Blood Disorders teams.
It was so inspiring to see the dedication, expertise, and collaboration that went into making this meeting such a success for Novo Nordisk.
In addition to the great work that went into our exhibit booth and many poster and oral presentations, ASH was an invaluable opportunity to engage directly with the hematology community.
We had meaningful conversations with KOLs where we shared the science and our vision for expanding treatment options for people living with rare blood disorders and sickle cell disease.
These dialogues will help shape our path forward and accelerate the impact of our future portfolio.
A huge thank you to everyone who worked so hard to bring this to life.
From our US Field and Home Office cross-functional teams and our partners in Global, everyone contributed to making the congress truly outstanding.
I’m excited for what lies ahead for the Rare Disease team at Novo Nordisk as we continue to educate with the goal of bringing innovative therapies to patients who need them most.”
Stay updated with Hemostasis Today.
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial